Helus Pharma has appointed Jill Conwell as chief people officer, effective immediately. Conwell brings more than 20 years of leadership experience in the life sciences industry, with expertise in organizational strategy, talent development, corporate communications and investor relations. She has previously held senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals and Shire Pharmaceuticals, where she helped build and scale organizations during periods of growth and pipeline advancement.
Helus Pharma said Conwell will help guide its talent strategy and organizational development as the company advances its clinical programs and prepares for its next phase of growth. The appointment comes at a critical time for the clinical-stage pharmaceutical company, which is developing novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity. These synthetic molecules are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
The company is currently developing HLP003, a proprietary novel serotonergic agonist in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. This candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, Helus Pharma is developing HLP004, another proprietary novel serotonergic agonist in Phase 2 for generalized anxiety disorder. The company maintains an extensive research portfolio of investigational novel serotonergic agonists.
For business and technology leaders monitoring the pharmaceutical and mental health sectors, this executive appointment signals Helus Pharma's preparation for potential commercialization and scaling operations. The strategic hiring of an experienced life sciences executive with organizational development expertise suggests the company is positioning itself for growth beyond clinical development phases. Conwell's background in investor relations and corporate communications also indicates the company's focus on stakeholder engagement as it advances through late-stage clinical trials.
The mental health treatment market represents significant commercial opportunity, with current treatments often showing limited efficacy or undesirable side effects. Helus Pharma's approach through novel serotonergic agonists aims to provide durable improvements in mental health, potentially disrupting traditional treatment paradigms. The company operates in Canada, the United States, the United Kingdom and Ireland, positioning it for global market access should its clinical programs prove successful.
For updates and more information about Helus Pharma, visit https://www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
